2. Search Result
Search Result
Results for "

E3 ligase activity

" in MedChemExpress (MCE) Product Catalog:

152

Inhibitors & Agonists

2

Screening Libraries

2

Peptides

2

Natural
Products

3

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-129395
    Mezigdomide
    2 Publications Verification

    CC-92480

    		 E1/E2/E3 Enzyme Molecular Glues Apoptosis Cancer
    Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating agent (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity .
    Mezigdomide
  • HY-101291
    Iberdomide
    10+ Cited Publications

    CC-220

    		 Ligands for E3 Ligase Apoptosis Molecular Glues Inflammation/Immunology Cancer
    Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities .
    Iberdomide
  • HY-153321
    Bexobrutideg
    1 Publications Verification

    NX-5948; BTK-IN-24

    		 PROTACs Btk Inflammation/Immunology Cancer
    Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
    Bexobrutideg
  • HY-N0170
    Indole-3-carbinol
    15+ Cited Publications

    Indole-3-methanol

    		 NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite Cancer
    Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
    Indole-3-carbinol
  • HY-175742
    BMS-986470

    		Molecular Glues Ligands for E3 Ligase Histone Acetyltransferase Cardiovascular Disease
    BMS-986470, a HbF-activating CRBN E3 ligase modulator (CELMoD), is an orally active dual molecular glue degrader targeting ZBTB7A and WIZ. BMS-986470 has potent γ-globin induction activity. BMS-986470 can be used for sickle cell disease (SCD) research .
    BMS-986470
  • HY-100507
    Avadomide
    5+ Cited Publications

    CC 122

    		 E1/E2/E3 Enzyme Apoptosis Molecular Glues NF-κB Inflammation/Immunology Cancer
    Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities .
    Avadomide
  • HY-108705
    BI-3802
    3 Publications Verification

    		 Molecular Glues Bcl-2 Family Cancer
    BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
    BI-3802
  • HY-110287
    Apcin
    5+ Cited Publications

    		 APC Mitosis Cancer
    Apcin, a ligand of Cdc20, is a potent and competitive anaphase-promoting complex/cyclosome (APC/C(Cdc20)) E3 ligase activity inhibitor. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. Apcin occupes the D-box-binding pocket on the side face of the WD40-domain and can prolong mitosis .
    Apcin
  • HY-173523
    KI-CDK9d-32

    		PROTACs CDK c-Myc Cancer
    KI-CDK9d-32 is a highly selective and potent CDK9 PROTAC degrader (DC50: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 exhibits anticancer activity against acute lymphoblastic leukemia and pancreatic cancer. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)) .
    KI-CDK9d-32
  • HY-123844
    dBET57
    4 Publications Verification

    		 PROTACs Epigenetic Reader Domain Apoptosis Cancer
    dBET57 is an effective and selective BRD4BD1 degrader based on PROTAC technology, with the ability to induce cell apoptosis and anti-tumor activity. dBET57 mediates the recruitment of the E3 ubiquitin ligase CRL4 Cereblon, showing a DC50/5h value of 500 nM for BRD4BD1 .
    dBET57
  • HY-131911
    PROTAC IDO1 Degrader-1

    		PROTACs Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology
    PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to Cereblon E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC50=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells .
    PROTAC IDO1 Degrader-1
  • HY-173011
    RJS308

    		PROTACs Cyclophilin HIV HCV Infection
    RJS308 is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 exhibits anti-HIV-1 and anti-HCV activities. RJS308 can be used in studies related to viral infections .
    RJS308
  • HY-161779
    PLX-3618

    		Molecular Glues Epigenetic Reader Domain Apoptosis Cancer
    PLX-3618 is a molecular glue, that degrades BRD4 with DC50 of 12.2 nM. PLX-3618 promotes polyubiquitination and subsequent proteasomal degradation of BRD4 by recruiting of the E3 ligase substrate receptor, DCAF11. PLX-3618 inhibits the proliferation of various cancer cells, induces apoptosis in AML cells. PLX-3618 exhibits antitumor activity against AML in mouse models .
    PLX-3618
  • HY-169329
    BIO-2007817

    		PINK1/Parkin E1/E2/E3 Enzyme Neurological Disease
    BIO-2007817 is a Parkin positive allosteric modulators (PAMs). BIO-2007817 enhances the activity of wildtype Parkin. BIO-2007817 stimulates Parkin (an E3 ligase)autoubiquitination and induces the appearance of monoubiquitinated forms of Miro1 (EC50: 0.17 μM) .
    BIO-2007817
  • HY-129531
    MuRF1-IN-1

    		E1/E2/E3 Enzyme Neurological Disease
    MuRF1-IN-1 is an orally active MuRF1 inhibitor. MuRF1-IN-1 can inhibit the interaction between MuRF1 and titin as well as E3 ligase activity. MuRF1-IN-1 can alleviate skeletal muscle atrophy and dysfunction in cardiac cachexia .
    MuRF1-IN-1
  • HY-111546
    BI-3663
    1 Publications Verification

    		 PROTACs FAK Cancer
    BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker . Anti-cancer activity .
    BI-3663
  • HY-143275
    HL-8

    		PROTACs PI3K Akt Cancer
    HL-8 is a PI3Kα PROTAC degrader. HL-8 promotes the ubiquitination and degradation of PI3Kα. HL-8 reduces pAKT levels. HL-8 has anticancer activity against colon and cervical cancer (Pink: PI3Kα ligand (HY-143277); Blue: E3 ligase VHL ligand (HY-138678); Black: linker (HY-W002042)) .
    HL-8
  • HY-128756
    SIAIS178

    		PROTACs Bcr-Abl Cancer
    SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity .
    SIAIS178
  • HY-169325
    (S)-ACE-OH

    		Molecular Glues Cancer
    (S)-ACE-OH is a molecular glue with anticancer activity. (S)-ACE-OH promotes nucleoporin degradation and disruption of nucleocytoplasmic trafficking by inducing the interaction between E3 ubiquitin ligase TRIM21 and nucleoporin NUP98 .
    (S)-ACE-OH
  • HY-145696
    SJ10542

    		PROTACs JAK Inflammation/Immunology Cancer
    SJ10542 is a potent and selective JAK2/3 PROTAC degrader. In PDX cells lSJBALL020589, SJ10542 has DC50 values of 14 and 11 nM for JAK2 and JAK3, respectively. SJ10542 exhibits antitumor activity and can be used for the research of hematological malignancies and autoimmune diseases . (Pink: Target protein ligand (HY-47073); Black: Linker (HY-W251248); Blue: E3 ligase ligand (HY-W890189); E3 ligase ligand+Linker (HY-176425))
    SJ10542
  • HY-141877
    MS4322
    1 Publications Verification

    YS43-22

    		 PROTACs Histone Methyltransferase Cancer
    MS4322 (YS43-22) is a specific PRMT5 PROTAC degrader. MS4322 reduces the PRMT5 protein level with a DC50 of 1.1 μM in MCF-7 cells. MS4322 inhibits the methyltransferase activity of PRMT5 with an IC50 of 18 nM. MS4322 promotes ubiquitination and degradation of PRMT5. MS4322 can be used for the research of breast cancer, lung cancer, and hepatocellular cancer. (Pink: PRMT5 ligand (HY-173092); Blue: E3 ligase ligand HY-112078); Black: linker (HY-124780); E3+linker (HY-173093 )) .
    MS4322
  • HY-164233
    YX968

    		PROTACs HDAC Apoptosis Cancer
    YX968 is a potent and selective HDAC3/8 PROTAC dual degrader with DC50 values of 1.7 and 6.8 nM. YX968 exhibits antitumor activity by promoting apoptosis .(Pink: Target protein ligand (HY-168287); Black: linker (HY-W007700); Blue: E3 ligase ligand (HY-112078))
    YX968
  • HY-163985
    PROTAC FGFR2 degrader 1

    		PROTACs FGFR Apoptosis Cancer
    PROTAC FGFR2 degrader 1 (compound N5) is a PROTAC that effectively targets FGFR2 with DC50 of 6.46 nM, the FGFR2 IC50 is 0.08 nM. PROTAC FGFR2 degrader 1 has anti-proliferative activity and highly selective, induces G0/G1 arrest of KATOIII and SNU16 cell cycle and inhibits apoptosis by reducing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. PROTAC FGFR2 degrader 1 inhibits gastric cancer cells remained above 50% at a concentration of 0.17 nM. PROTAC FGFR2 degrader 1 potently inhibits the growth of SNU16 xenograft tumors in mouse model (Structure Note: Pink, FGFR2 activator: HY-18708; Blue, E3 ligase ligand: HY--10984; Black, linker: HY-163989; E3 ligase ligand + linker：HY-163986) .
    PROTAC FGFR2 degrader 1
  • HY-162943
    P60-L3-VHL

    		PROTACs Cancer
    P60-L3-VHL is a PROTAC-class Foxp3 degrader. P60-L3-VHL reduced cell differentiation and Foxp3 expression in activated Treg cells in vitro and had anti-tumor activity (Blue: E3 ligase ligand (HY-162945); Pink: target protein ligand (HY-162946); Black: linker (HY-162947)) .
    P60-L3-VHL
  • HY-174996
    NEP162

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    NEP162 is a BRD4 PROTAC degrader with DC50s of 1.2 and 1.6 μM in SW480 and U2OS cells. NEP162 exhibits antiproliferative activity, effectively inhibits tumor growth and induces apoptosis. NEP162 can be used for the study of osteosarcoma, colorectal cancer and non-small cell lung cancer, etc. (Pink: BRD4 ligand : (HY-78695), Blue: E3 ligase Ligand (HY-D2259), BLACK: Linker, E3 ligase ligand-linker conjugate (HY-174997)) .
    NEP162
  • HY-170669
    PROTAC XPO1 degrader-1

    		PROTACs CRM1 Apoptosis NF-κB Cancer
    PROTAC XPO1 degrader-1 (Compound 2c) is an XPO1 degrader. PROTAC XPO1 degrader-1 exhibits anti-proliferative effects, can induce cell apoptosis, inhibit NF-κB activity, and cause cell cycle arrest in the G1 phase. PROTAC XPO1 degrader-1 can be used in research on hematological malignancies (Pink: Target Protein Ligand (HY-170672); Black: Linker (HY-W010525); Blue: E3 Ligase Ligand (HY-170671); E3 Ligase Ligand-Linker Conjugate (HY-170673)) .
    PROTAC XPO1 degrader-1
  • HY-130256
    β-NF-JQ1

    		PROTACs Epigenetic Reader Domain Cancer
    β-NF-JQ1 is a PROTAC that recruits Aryl Hydrocarbon Receptor E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity .
    β-NF-JQ1
  • HY-173011A
    RJS308 TFA

    		PROTACs Cyclophilin HIV HCV Infection
    RJS308 TFA is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 TFA induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 TFA exhibits anti-HIV-1 and anti-HCV activities. RJS308 TFA can be used in studies related to viral infections .
    RJS308 TFA
  • HY-150839
    E3 ligase Ligand PG

    		Ligands for E3 Ligase Cancer
    E3 ligase Ligand PG is a E3 ligase ligand that can be used in the recruitment of CRBN protein. E3 ligase Ligand PG exhibits potent binding activity with CRBN (IC50 of 2.191 μM). E3 ligase Ligand PG can be connected to the BMS-202 (HY-19745) by a linker to form PROTAC, PROTAC PD-L1 degrader-1 (HY-163757) .
    E3 ligase Ligand PG
  • HY-175358
    PROTAC USP7 Degrader-1

    		PROTACs Deubiquitinase Cancer
    PROTAC USP7 Degrader-1 is a VHL-recruiting PROTAC and USP7 degrader with binding activity to both USP7 and the VHL E3 ubiquitin ligase. PROTAC USP7 Degrader-1 recruits the VHL E3 ligase to mediate the ubiquitination and subsequent proteolytic degradation of USP7 .
    PROTAC USP7 Degrader-1
  • HY-148602
    KH-4-43
    1 Publications Verification

    		 E1/E2/E3 Enzyme Cancer
    KH-4-43 is an inhibitor of E3 CRL4. KH-4-43 inhibits E3 CRL4's core ligase complex and exhibits anticancer activity. KH-4-43 has a binding Kd to E3 ROC1-CUL4A CTD or the highly related ROC1-CUL1 CTD at 83 nM or 9.4 μM, respectively .
    KH-4-43
  • HY-172798
    XZ338

    		Bcl-2 Family Cancer
    XZ338 is a highly selective degrader targeting BCL-XL. XZ338 does not degrade BCL-2. XZ338 inhibits MOLT-4 cells with a IC50 value of 3.7 nM. XZ338 has anti-proliferative activity. XZ338 can be used for anti-cancer study. (Target protein ligand: HY-19741; E3 ligase: HY-112078; linker: HY-172799; E3+liner: HY-172800) .
    XZ338
  • HY-N0170R
    Indole-3-carbinol (Standard)

    Indole-3-methanol (Standard)

    		 NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite Reference Standards Cancer
    Indole-3-carbinol (Standard) is the analytical standard of Indole-3-carbinol. This product is intended for research and analytical applications. Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
    Indole-3-carbinol (Standard)
  • HY-148106
    MEL23

    		Ligands for E3 Ligase Cancer
    MEL23 is a MDM2 E3 ligase inhibitor that blocks the E3 ligase activity of the MDM2-MDMX complex. MEL23 inhibits Mdm2 and p53 ubiquitination in cells, reduce viability of cells with wild-type p53. MEL23 stabilizes MDM2 via a mechanism independent of p53 transcription .
    MEL23
  • HY-W062696
    BC-1382

    		E1/E2/E3 Enzyme Inflammation/Immunology
    BC-1382 is a potent ubiquitin E3 ligase HECTD2 inhibitor that specificly disrupts the HECTD2/PIAS1 interaction (IC50≈ 5 nM).Anti-inflammatory activity .
    BC-1382
  • HY-101291R
    Iberdomide (Standard)

    CC-220 (Standard)

    		 Reference Standards Ligands for E3 Ligase Apoptosis Molecular Glues Inflammation/Immunology Cancer
    Iberdomide (Standard) is the analytical standard of Iberdomide. This product is intended for research and analytical applications. Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities .
    Iberdomide (Standard)
  • HY-141877B
    MS4322 (isomer)

    YS43-22 (isomer)

    		 PROTACs Histone Methyltransferase Cancer
    MS4322 (YS43-22) isomer is an isomer of MS4322. MS4322 is a specific PRMT5 PROTAC degrader. MS4322 reduces the PRMT5 protein level with a DC50 of 1.1 μM in MCF-7 cells. MS4322 inhibits the methyltransferase activity of PRMT5 with an IC50 of 18 nM. MS4322 promotes ubiquitination and degradation of PRMT5. MS4322 can be used for the research of breast cancer, lung cancer, and hepatocellular cancer. (Pink: PRMT5 ligand (HY-173092); Blue: E3 ligase ligand HY-112078); Black: linker (HY-124780); E3+linker (HY-173093 )) .
    MS4322 (isomer)
  • HY-175025
    CH091138

    		PROTACs Ras Apoptosis Cancer
    CH091138 is a potent and selective KRASG12D PROTAC degrader with DC50s of 148.3 nM in HeLa cells and 469.8 nM in AsPC-1 cells. CH091138 selectively degrades exogenous and endogenous KRASG12D but not KRAS WT or other KRAS mutants (G12C/G12S/G12V), depending on the VHL-mediated ubiquitin-proteasome system. CH091138 exhibits potent anti-tumor activity and induces cancer cell apoptosis. CH091138 can be used for the studies of pancreatic cancer and colon cancer. (Pink: KRASG12D ligand (HY-175144); Blue: VHL E3 ligase ligand (HY-138678); Black: Linker; VHL E3 ligase ligand + Linker (HY-136006B)) .
    CH091138
  • HY-163168
    aTAG 4531

    CFT-4531

    		 PROTACs DNA/RNA Synthesis Cancer
    aTAG 4531 (CFT-4531) is a potent, selective, and onmechanism tool degrader of MTH1 with DC50 value of 0.28 nM and Ki value of 1.8 nM. The degradation activity is due to the intricate formation of the ternary complex between the MTH1 aTAG, CRBN E3 ligase, and aTAG tool degrader. Red: MTH1 aTAG inhibitor (HY-134725), Blue: CRBN ligand (HY-126457), Black: linker (HY-108374) .
    aTAG 4531
  • HY-173422
    MS2133

    		PROTACs Histone Methyltransferase Cancer
    MS2133 is a DOT1L PROTAC degrader. MS2133 promotes ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells (DC50: 56 nM and 25 nM, respectively), and reduces H3K79 methylation. MS2133 inhibits the growth of MLL-r leukemia cells and has anticancer activity. (Pink: DOT1L ligand (HY-173423); Blue: E3 ligase VHL ligand (HY-47070); Black: Linker (HY-79577); E3 ligase VHL ligand-linker conjugate (HY-173424)) .
    MS2133
  • HY-174445
    C199

    		PROTACs Histone Methyltransferase Apoptosis Cancer
    C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity (Pink: Target protein ligand (HY-111109); Blue: E3 ligase ligand (HY-112078), E3 ligase ligand + linker (HY-174474); black: Linker) .
    C199
  • HY-178803
    PROTAC BCL6 Degrader-2

    		PROTACs BCL6 Cancer
    PROTAC BCL6 Degrader-2 (Compound A19) is an orally active, selective BCL6 PROTAC degrader (DC50s: 34 pM in OCI-LY1 cells and 0.45 nM in HEK293T cells). PROTAC BCL6 Degrader-2 promotes the ubiquitination and degradation of BCL6. PROTAC BCL6 Degrader-2 exhibits anticancer activity against BCL6-dependent diffuse large B-cell lymphoma (Pink: BCL6 ligand (HY-178804); Blue: E3 ligase ligand (HY-W087383); E3 ligase ligand + linker (HY-W998306)) .
    PROTAC BCL6 Degrader-2
  • HY-130617
    Pomalidomide-amido-C1-Br

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity .
    Pomalidomide-amido-C1-Br
  • HY-157213
    LWY713

    		Apoptosis PROTACs FLT3 Cancer
    LWY713 is a PROTAC-class FLT3 degrader (DC50=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).
    LWY713
  • HY-176440
    BP-198

    		Virus Protease SARS-CoV PROTACs Infection
    BP-198 is an Mpro PROTAC degrader. BP-198 promotes the ubiquitination and degradation of Mpro. BP-198 has antiviral effects against SARS-CoV-2 (IC50: 11.8 μM) and has stronger activity against drug-resistant viruses. (Pink: target protein ligand (HY-176442); blue: E3 ligase ligand (HY-176441); black: linker (HY-W457968); E3 ligase-linker conjugate (HY-176443)) .
    BP-198
  • HY-175887
    Pomalidomide-C9-Br

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Pomalidomide-C9-Br is a synthesized E3 ligase ligand-linker conjugate that can be used to synthesize PROTAC EGFR degrader 15 (HY-175839). PROTAC EGFR degrader 15 is a potent EGFR PROTAC degrader with anti-cancer activity .
    Pomalidomide-C9-Br
  • HY-169232
    PCC16 chloride

    		PROTACs Cancer
    PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
    PCC16 chloride
  • HY-155075
    NC-R17

    		PROTACs Glutathione Peroxidase Ferroptosis Cancer
    NC-R17 is a PROTAC-class, non-covalent GPX4 degrader based on RSL3, involved in ferroptosis. NC-R17 has antitumor activity and is used for non-covalent GPX4 PROTAC design . NC-R17 consists of a target protein ligand (red part) Demethyl-RSL3 (HY-135832); an E3 ubiquitin ligase ligand (blue part) Lenalidomide (HY-A0003) and a PROTAC linker (black part) (HY-169376). E3 ubiquitin ligase and linker can form Lenalidomide-C13-piperazine-Boc (HY-169377) .
    NC-R17
  • HY-100507A
    Avadomide hydrochloride

    CC 122 hydrochloride

    		 E1/E2/E3 Enzyme Apoptosis Molecular Glues NF-κB Inflammation/Immunology Cancer
    Avadomide hydrochloride (CC 122 hydrochloride) is the hydrochloride form of Avadomide (HY-100507). Avadomide hydrochloride is an orally active cereblon modulator. Avadomide hydrochloride modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide hydrochloride exhibits potent antitumor and immunomodulatory activities .
    Avadomide hydrochloride
  • HY-173250
    YN14-H

    		PROTACs Ras Apoptosis Cancer
    YN14-H is a PROTAC degrader targeting KRAS G12C. YN14-H inhibits cell growth in NCI-H358 and MIA PaCa-2 cells (IC50 values of 0.042, 0.021 μM, DC50 values of 28.9, 18.1 nM, respectively). YN14-H significantly induces apoptosis and inhibits migration. YN14-H demonstrates favorable pharmacokinetic properties and excellent antitumor activity in vivo. (Structure Note: Pink: target protein ligand (HY-173252); Blue: E3 ligase ligand (HY-125905); Black: linker (HY-Y0840); E3 ligase ligand + linker (HY-173253) .
    YN14-H

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: